671215-76-2

Basic information

• Product Name: 4-CHLOROMETHYL-2-(2-FLUORO-PHENYL)-5-METHYL-OXAZOLE
• Synonyms: CHEMBRDG-BB 4005944;4-CHLOROMETHYL-2-(2-FLUORO-PHENYL)-5-METHYL-OXAZOLE;4-(chloromethyl)-2-(2-fluorophenyl)-5-methyl-1,3-oxazole(SALTDATA: FREE);4-(chloromethyl)-2-(2-fluorophenyl)-5-methyl-1,3-oxazole
• CAS NO: 671215-76-2
• Molecular Formula: C₁₁H₉ClFNO
• Molecular Weight: 225.65
• Mol File: 671215-76-2.mol

Chemical Properties

• Boiling Point: 341.4 °C at 760 mmHg
• Flash Point: 160.3 °C
• Appearance: /
• Density: 1.261 g/cm³
• Vapor Pressure: 0.000159mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 4-CHLOROMETHYL-2-(2-FLUORO-PHENYL)-5-METHYL-OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROMETHYL-2-(2-FLUORO-PHENYL)-5-METHYL-OXAZOLE(671215-76-2)
• EPA Substance Registry System: 4-CHLOROMETHYL-2-(2-FLUORO-PHENYL)-5-METHYL-OXAZOLE(671215-76-2)

Safety Data

• Hazardous Substances Data: 671215-76-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloromethyl-2-(2-fluoro-phenyl)-5-methyl-oxazole is used as a building block for the synthesis of other organic compounds, particularly in the development of new drugs. Its unique structure and properties suggest potential biological activity, making it an interesting target for further research and exploration in medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Chloromethyl-2-(2-fluoro-phenyl)-5-methyl-oxazole serves as a starting material for the creation of a variety of complex organic compounds. Its versatile functional groups allow for multiple synthetic pathways, contributing to the advancement of chemical research and the development of novel materials and pharmaceuticals.

InChI:InChI=1/C11H9ClFNO/c1-7-10(6-12)14-11(15-7)8-4-2-3-5-9(8)13/h2-5H,6H2,1H3

Upstream product

• 446-52-6 2-Fluorobenzaldehyde 
• 933236-25-0 2-(2-fluorophenyl)-4,5-dimethyloxazole 3-oxide 

Downstream Products

• 1593269-77-2 2-(4-{[{[2-(2-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoic acid 
• 1593269-64-7 tert-butyl 2-(4-{[{[2-(2-fluorophenyl)-5-methyl-1,3-oxazol-4-yl] methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoate 

Relevant articles and documents

Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties

We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitter-ionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound possessed fatal issues such as potent cytochrome P450 (CYP)3A4 direct inhibitory activity. Thus, we carried out the medicinal optimization to improve these while maintaining the potent PPAR agonistic activity. As a result, the issues were addressed by changing the furan ring to a low lipophilic 1,3,4-oxadiazole ring. Additionally, these oxadiazole derivatives exhibited a significant decrease in plasma glucose and plasma triglyceride levels without marked weight gain.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

In the quest for novel PPARα/γ co-agonists as putative drugs for the treatment of type 2 diabetes and dyslipidemia, we have used a structure-based design approach to identify propionic acids with a 1,5-disubstituted indole scaffold as potent PPARα/γ activ

Indolyl derivatives as liver-X-receptor (LXR) modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.